4D MOLECULAR THERAPEUTICS
4D Molecular Therapeutics is a biotechnology company.The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.
4D MOLECULAR THERAPEUTICS
Industry:
Biotechnology Genetics
Founded:
2013-01-01
Address:
Emeryville, California, United States
Country:
United States
Website Url:
http://www.4dmoleculartherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(510) 505-2680
Total Funding:
175 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
BioMarin Pharmaceutical
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
Bluebird Bio
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Fulgent Therapeutics
Fulgent Therapeutics, LLC is a pharmaceutical company focusing on developing and commercializing innovative cancer therapeutics.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
NGM Biopharmaceuticals
NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.
Purigen Biosystems
Purigen Biosystems' innovative products offer a truly transformative automated solution for DNA and RNA purification.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Longevity Vision Fund
Longevity Vision Fund investment in Series C - 4D Molecular Therapeutics
MiraeAsset Financial Group
MiraeAsset Financial Group investment in Series C - 4D Molecular Therapeutics
BVF Partners
BVF Partners investment in Series C - 4D Molecular Therapeutics
Pappas Capital
Pappas Capital investment in Series C - 4D Molecular Therapeutics
Chiesi Ventures
Chiesi Ventures investment in Series C - 4D Molecular Therapeutics
Viking Global Investors
Viking Global Investors investment in Series C - 4D Molecular Therapeutics
QUAD Investment Management
QUAD Investment Management investment in Series C - 4D Molecular Therapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Series C - 4D Molecular Therapeutics
Berkeley Catalyst Fund (BCF)
Berkeley Catalyst Fund (BCF) investment in Series C - 4D Molecular Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series C - 4D Molecular Therapeutics
Official Site Inspections
http://www.4dmoleculartherapeutics.com Semrush global rank: 4.03 M Semrush visits lastest month: 3.04 K
Unable to get host informations!!!
More informations about "4D Molecular Therapeutics"
About | 4DMT - 4D Molecular Therapeutics
4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market diseases.See details»
4D Molecular Therapeutics - Crunchbase Company …
4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.See details»
Investors & Media | 4D Molecular Therapeutics
4DMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. 4DMT is striving to unlock the full potential of genetic medicines …See details»
4D Molecular Therapeutics - LinkedIn
4D Molecular Therapeutics | 15,822 followers on LinkedIn. Powering the Future of Genetic Medicines | 4DMT is a clinical stage biopharma company inventing and developing innovative products to ...See details»
Release Details - 4D Molecular Therapeutics
Poised for multiple meaningful catalysts in 2024 driven by strong clinical progress across large market programs in wet age-related macular degeneration (wet AMD), diabetic macular …See details»
Patients | 4DMT - 4D Molecular Therapeutics
4D-150 is being evaluated in the currently-enrolling PRISM clinical trial, a Phase 1/2 dose-escalation and randomized, controlled, masked expansion study of intravitreal 4D-150 in adults with wet AMD.The primary endpoints of the study …See details»
4D Molecular Therapeutics - Craft
Oct 4, 2024 4D Molecular Therapeutics has 5 employees at their 1 location and $20.72 m in annual revenue in FY 2023. See insights on 4D Molecular Therapeutics including office …See details»
Release Details - 4D Molecular Therapeutics
Oct 26, 2022 4D Molecular Therapeutics to host a conference call on November 3rd, 4:30 pm E.T. EMERYVILLE, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, …See details»
4D Molecular Therapeutics, Inc. (FDMT) - Yahoo Finance
Find the latest 4D Molecular Therapeutics, Inc. (FDMT) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Release Details - 4D Molecular Therapeutics
EMERYVILLE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed …See details»
4DMT Receives FDA Regenerative Medicine Advanced Therapy
Dec 21, 2023 4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First …See details»
Technology | 4DMT - 4D Molecular Therapeutics
Viruses have naturally evolved to infect cells and, in so doing, deliver their genetic contents into cells. Investigators in the field have engineered viruses for safety (removing their disease …See details»
Release Details - 4D Molecular Therapeutics
EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed …See details»
4D Molecular Therapeutics, Inc. (FDMT) Stock Price, News, Quote ...
Find the latest 4D Molecular Therapeutics, Inc. (FDMT) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
4D Molecular Therapeutics: Pioneering Gene Therapies …
Jul 10, 2023 Summary. 4D Molecular Therapeutics demonstrates a robust economic position and promising line-up of gene therapies, with a commitment to innovation and strategic …See details»
Release Details - 4D Molecular Therapeutics
Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies, each demonstrating …See details»
Pipeline | 4DMT - 4D Molecular Therapeutics
4D-175 combines the customized and evolved intravitreal vector, R100, and a codon-optimized transgene encoding a highly functional shortened form of human complement factor H …See details»
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 …
Sep 19, 2024 4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow …See details»
Release Details - 4D Molecular Therapeutics
Feb 3, 2024 51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden (mean of 10 anti-VEGF …See details»